ArticleCJEM2026
A scoping review of emergency department take-home naloxone on patient and health outcomes.
Article in CJEM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe opioid crisis in North America continues to cause immense harm and loss of life. The distribution of naloxone has been recognized as an important tool to combat the opioid crisis. The emergency department (ED) setting provides an important opportunity to distribute naloxone to people that use opioids. The purpose of this scoping review was to summarize the literature surrounding ED-based take-home naloxone with a focus on key patient-centered health outcomes.
methodsWe performed a scoping review of naloxone distribution from the ED utilizing PRISMA Extension for Scoping Reviews guidelines. The databases MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched for keywords related to naloxone and the ED. Abstracts were screened for relevance and a full text review was undertaken applying inclusion and exclusion criteria. Data were extracted and summarized by outcome of interest.
results3475 studies were identified and screened for relevance. 24 studies were included in the results and analysis. Seven studies reported health outcomes related to take-home naloxone. Nine studies reported patient perceptions of take-home naloxone, and eight studies reported provider perceptions of take-home naloxone. No studies were identified that reported cost-effectiveness data. We found that take-home naloxone distribution in the ED setting is supported by both patients and ED providers. Knowledge gaps exist as to whether these programs are effective to improve patient health outcomes, or whether they are cost-effective.
conclusionsTake-home naloxone distribution in the ED setting to combat the opioid overdose crisis is supported by patients and ED providers. Knowledge gaps exist as to whether these programs improve health outcomes for people who use opioids, or whether they are cost-effective. Take-home naloxone should be considered as part of a harm reduction strategy for patients presenting to the ED at risk for opioid overdose.
Indexed as
Identifiers
42322519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.